NICE Backs Novartis's Tasigna For CML, Rejects BMS's Sprycel

LONDON (Dow Jones)--The U.K.'s health-cost regulator Friday backed Novartis AG's (NOVN.VX) cancer drug Tasigna for first-line treatment of chronic myeloid leukemia after the Swiss drug maker offered a discount, but Bristol-Myers Squibb Co.'s (BMY) rival product Sprycel was rejected.

The decision from the ...

Copyright 2012 Dow Jones & Company, Inc. All Rights Reserved

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit

www.djreprints.com

Available to asia.WSJ.com subscribers

  • Beijing, U.S. Unveil New Korean Sanctions

    The U.S. and China introduced a new round of sanctions against North Korea at the United Nations that the U.S. said would significantly impede the development of Pyongyang's nuclear and missile programs, in response to its test last month of an atomic bomb.

  • Five Stocks Handled the Heavy Lifting

    Five blue-chip stocks have accounted for about one-third of the rally in the Dow since the financial crisis.